Journey Clinical key facts
- Developer of an online healthcare platform designed to assist psychotherapists in growing their practice with psychedelic therapy.
- It has raised $26.6M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($8.5M) in Mar 2023.
- Notable investors include FJ Labs, Gaingels, Calm Ventures, AlleyCorp, Union Square Ventures — 26 tracked in total.
- Status: Privately Held (backing).
Who backs Journey Clinical
26+Membership and data by Private Market View
- ·The complete investor list: 26 names
- ·Watch Journey Clinical: the Monday email on marks, rounds and moves
Journey Clinical funding rounds
1 roundsHow much has Journey Clinical raised?
Journey Clinical has raised $26.6 million in total; 1 of its rounds is on record. The largest on record was an $8.5 million Series A in Mar 2023.
Journey Clinical investors
26 investors are on record for Journey Clinical, including FJ Labs, Gaingels, Calm Ventures and AlleyCorp. By type, the record holds 9 venture capital firms, 1 private equity firm and 1 growth equity firm. The Series A in Mar 2023 drew 14 investors.
About Journey Clinical
Developer of an online healthcare platform designed to assist psychotherapists in growing their practice with psychedelic therapy. The company provides independent licensed mental health and private psychotherapy practitioners with the prescription services they need, enabling health professionals to provide safe, effective, and transformative ketamine-assisted psychotherapy for their patients.
- Industry
- Clinics/Outpatient Services
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 45
- Website
- journeyclinical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Journey Clinical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.